News & Updates

Among patients with atrial fibrillation (AF), statin use was associated with a significantly lower risk of stroke or transient ischaemic attack (TIA) compared with non-use, according to a study presented at EHRA 2023.

Nearly two in three participants in the placebo arm of nonalcoholic steatohepatitis (NASH) randomized clinical trials (RCTs) experience an adverse event (AE), while one in 10 have a serious AE, according to a pooled analysis of studies with NASH placebo.

Treatment with bevantolol hydrochloride (SOM3355) is well tolerated and results in a reduction in chorea among patients with Huntington’s disease (HD), a study has shown.

The use of cloxacillin alone is just as good as the combination of cloxacillin plus fosfomycin in terms of achieving treatment success among hospitalized patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia, according to the results of the open-label, phase IV-III SAFO trial presented at the ECCMID 2023.

The addition of pembrolizumab to standard chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, regardless of whether they had mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease, according to the NRG-GY018 trial presented at the SGO 2023.